Repare Therapeutics (NASDAQ: RPTX)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-09 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.860 | -0.910 | -0.0500 | ||||
REV | 679.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Repare Therapeutics (NASDAQ: RPTX) through any online brokerage.
Other companies in Repare Therapeutics’s space includes: Humacyte (NASDAQ:HUMA), bluebird bio (NASDAQ:BLUE), Precigen (NASDAQ:PGEN), Eagle Pharmaceuticals (NASDAQ:EGRX) and Tango Therapeutics (NASDAQ:TNGX).
The latest price target for Repare Therapeutics (NASDAQ: RPTX) was reported by Morgan Stanley on Monday, August 8, 2022. The analyst firm set a price target for 28.00 expecting RPTX to rise to within 12 months (a possible 133.33% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Repare Therapeutics (NASDAQ: RPTX) is $12 last updated Today at August 18, 2022, 5:03 PM UTC.
There are no upcoming dividends for Repare Therapeutics.
Repare Therapeutics’s Q3 earnings are confirmed for Wednesday, November 9, 2022.
There is no upcoming split for Repare Therapeutics.
Repare Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.